Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets

Ryan D. Michalek, Valerie A. Gerriets, Sarah R. Jacobs, Andrew N. Macintyre, Nancie J. MacIver, Emily F. Mason, Sarah A. Sullivan, Amanda G. Nichols and Jeffrey C. Rathmell
J Immunol March 15, 2011, 186 (6) 3299-3303; DOI: https://doi.org/10.4049/jimmunol.1003613
Ryan D. Michalek
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
†Department of Immunology, Duke University Medical Center, Durham, NC 27710;
‡Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27710; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valerie A. Gerriets
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah R. Jacobs
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
†Department of Immunology, Duke University Medical Center, Durham, NC 27710;
‡Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27710; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew N. Macintyre
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
†Department of Immunology, Duke University Medical Center, Durham, NC 27710;
‡Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27710; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancie J. MacIver
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
§Department of Pediatrics, Duke University Medical Center, Durham, NC 27710
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily F. Mason
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah A. Sullivan
†Department of Immunology, Duke University Medical Center, Durham, NC 27710;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda G. Nichols
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey C. Rathmell
*Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710;
†Department of Immunology, Duke University Medical Center, Durham, NC 27710;
‡Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27710; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Teff and Treg CD4+ T cell subsets exhibit distinct metabolic profiles. CD4+ T cells from wild-type (A, C–E) or Glut1-myc (B) knockin mice were cultured to enrich Teff (Th1, Th2, Th17) and Treg subsets. After 3 d, cells were washed and cultured 2 d in IL-2 alone and analyzed by immunoblot (A), surface staining of endogenous Glut1-myc (B) with anti-Myc Ab followed by gating on each T cell subset as determined by intracellular cytokine staining, glycolysis (C), mitochondrial potential by tetramethylrhodamine ethyl ester staining (D), and palmitate oxidation (E). Naive CD4+ T cells or cells activated in the presence of the CPTI inhibitor Etx are shown as controls. F, Percentage of splenic cytokine+ CD4+ T cells from >1 y aged Glut1 transgenic (n = 6) and nontransgenic (n = 5) mice following stimulation intracellular cytokine staining for IFN-γ, IL-4, and IL-17. The percentage of Foxp3+ cells was assessed ex vivo by intracellular staining. Results are from three independent experiments with average and SD determined using the Student t test. *p ≤ 0.05.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Lipid oxidation promotes Treg generation and suppresses Teff function and survival. A, CD4+ T cells were stimulated in conditions to enrich for Th1 cells and Treg in the presence or absence of Etx and assessed by intracellular cytokine and Foxp3 staining. CD4+ T cells were cultured in Teff and Treg skewing cultures in the presence or absence of exogenous FA, washed, and examined for function by intracellular cytokine staining or in a T cell suppressor assay (B) and expression of CD4+ lineage commitment transcription factors by flow cytometry (C). D, Th cell subsets were generated, washed, and replated an additional 2 d in IL-2 and a further 2 d in the presence or absence of FA in parallel wells to measure cell viability and cytokine production in each condition. The number of viable cytokine-producing cells was then calculated for each condition. Results are representative of three independent experiments with average and SD determined using the Student t test. *p ≤ 0.05.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    AMPK and mTOR regulate lipid oxidation and enrich Treg differentiation in vivo. A, CD4+ T cells were stimulated with anti-CD3 and anti-CD28 for 18 h, washed, and replated in the presence of anti-CD3 alone, 25 nM rapamycin (Rapa), 2 ng/ml TGFβ, 200 μM Etx, or 10 mM FA for an additional 48 h followed by intracellular Foxp3 staining. B, Immunoblot of Th cultures, naive CD4+ T cells, and natural Tregs. C–E, Mice were sensitized to OVA in the presence of Met or a PBS followed by aerosol challenge 21 d later and analyzed by intracellular Glut1 staining in CD4+ CD44lowT cells (solid gray) and CD4+ CD44high T cells in the draining lymph node of the lung from mice treated with (black line) or without (gray line) Met (C). In addition, the percentage (D) and number (E) of CD4+ Foxp3+ cells and total CD4+ T cells in the draining lymph node following aerosol challenge were determined. Results are representative of three independent experiments with average and SD determined using the Student t test. *p ≤ 0.05.

Additional Files

  • Figures
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Figures 1-2 (PDF, 345 Kb) - Description:
      Figure 1. Teff cells exhibit increased glucose uptake compared to Treg cells and selective accumulation in Glut1 transgenic mice in vivo.
      Figure 2. Lipid oxidation and AMPK activation promote Treg generation in vitro and in a murine model of asthma.
PreviousNext
Back to top

In this issue

The Journal of Immunology: 186 (6)
The Journal of Immunology
Vol. 186, Issue 6
15 Mar 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
Ryan D. Michalek, Valerie A. Gerriets, Sarah R. Jacobs, Andrew N. Macintyre, Nancie J. MacIver, Emily F. Mason, Sarah A. Sullivan, Amanda G. Nichols, Jeffrey C. Rathmell
The Journal of Immunology March 15, 2011, 186 (6) 3299-3303; DOI: 10.4049/jimmunol.1003613

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
Ryan D. Michalek, Valerie A. Gerriets, Sarah R. Jacobs, Andrew N. Macintyre, Nancie J. MacIver, Emily F. Mason, Sarah A. Sullivan, Amanda G. Nichols, Jeffrey C. Rathmell
The Journal of Immunology March 15, 2011, 186 (6) 3299-3303; DOI: 10.4049/jimmunol.1003613
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved
  • Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil
  • Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice
Show more CUTTING EDGE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606